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Prolonged contact with dendritic cells turns lymph
node-resident NK cells into anti-tumor effectors
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Abstract
Natural killer (NK) cells are critical players against tumors. The
outcome of anti-tumor vaccination protocols depends on the effi-
ciency of NK-cell activation, and efforts are constantly made to
manipulate them for immunotherapeutic approaches. Thus, a
better understanding of NK-cell activation dynamics is needed.
NK-cell interactions with accessory cells and trafficking between
secondary lymphoid organs and tumoral tissues remain poorly
characterized. Here, we show that upon triggering innate immu-
nity with lipopolysaccharide (LPS), NK cells are transiently acti-
vated, leave the lymph node, and infiltrate the tumor, delaying its
growth. Interestingly, NK cells are not actively recruited at the
draining lymph node early after LPS administration, but continue
their regular homeostatic turnover. Therefore, NK cells resident in
the lymph node at the time of LPS administration become acti-
vated and exert anti-tumor functions. NK-cell activation correlates
with the establishment of prolonged interactions with dendritic
cells (DCs) in lymph nodes, as observed by two-photon microscopy.
Close DC and NK-cell contacts are essential for the localized deliv-
ery of DC-derived IL-18 to NK cells, a strict requirement in NK-cell
activation.
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Introduction
Natural killer (NK) cells are lymphocytes endowed with germ-line-
encoded receptors that do not undergo somatic rearrangements.
Due to the absence of clonally distributed receptors, NK cells are
classified as innate lymphocytes. NK cells are among the first
lymphocytes involved in sensing host cell modifications due to
infections or to tumor transformation (Moretta et al, 2014). In
several types of inflammatory processes, NK lymphocytes are the
earliest source of pro-inflammatory cytokines, particularly IFN-c,
which, in turn, potently activates macrophages, initiating type I
innate (M1) and adaptive (Th1) immunity (Martin-Fontecha et al,
2004; Agaugue et al, 2008; Kupz et al, 2013; Lee et al, 2015).
Activation of type I immunity is essential not only to adequately
respond to viral or bacterial infections but also for tumor immuno-
surveillance. Accordingly, low levels of NK-cell activity usually
correlate with a high risk to develop cancer, and high numbers of
NK cells in the tumor microenvironment correlate with improved
prognosis of tumor-affected patients (Desbois et al, 2012).
Understanding the mechanisms and the dynamics of NK-cell
responses, including the timing and site of NK-cell activation, is
therefore important to improve anti-tumor immunotherapies. A
common feature of tumor growth is the capacity of tumor cells to
create an immunosuppressive microenvironment. Therapeutic
strategies aimed at generating appropriate inflammatory conditions
to reactivate immunosurveillance are based on cytokine administra-
tion or vaccination, as well as treatments with Gram-negative and
Gram-positive bacteria (Toussaint et al, 2013; Lin et al, 2015;
Thompson et al, 2015). Considering the potent pro-inflammatory
activity of NK cells, it would be desirable to design vaccination
protocols that strongly boost NK-cell activation.
NK-cell activation depends on the balance between activating
and inhibitory signals transduced by germ-line-encoded receptors.
Over the last few decades, it has been clearly demonstrated that
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NK-cell activation is dictated by the interaction with accessory cells
producing activating mediators in both mice and humans. Dendritic
cells (DCs) were the first described accessory cells capable of
promoting IFN-c production and cytotoxic activity by NK cells
(Fernandez et al, 1999). Among the various DC-derived cytokines
required for optimal NK-cell activation, IL-2 and IL-18 have been
amply used in anti-tumor preclinical and clinical approaches
(Skrombolas & Frelinger, 2014) (Fabbi et al, 2015). Interestingly,
the therapeutic efficacy of these cytokines strongly correlates with
their capacity to stimulate NK cells (Colucci et al, 2002).
Although we now have substantial understanding of the mecha-
nisms underlying NK-cell activation, NK-cell trafficking between
secondary lymphoid organs and inflamed or tumoral tissues and the
dynamics of NK-cell interactions with accessory cells have been
largely overlooked.
For instance, it is known that in resting conditions, NK cells
reside in tissues and lymph nodes. NK cells home to lymph nodes
via high endothelial venules (HEVs) and, presumably, also via the
afferent lymphatics. The latter speculation is based on the observa-
tion that NK cells are present in the afferent lymph drained from
healthy tissues (Carrega et al, 2014). In inflamed conditions, NK
cells can be directly activated and recruited by DCs at the draining
lymph nodes (Martin-Fontecha et al, 2004; Zanoni et al, 2005;
Lucas et al, 2007). Whether lymph node-resident or newly recruited
NK cells acquire anti-tumor effector functions following interaction
with activated DCs is still unclear. It remains also to be determined
whether anti-tumor effector functions can be exerted by tissue- or
tumor-resident NK cells activated by accessory cells outside the
secondary lymphoid organs. Moreover, while DCs and NK cells
have been observed to form immune synapses (IS) enriched in
surface and soluble molecules required for the activation of NK cells
(Borg et al, 2004; Barreira da Silva et al, 2011) in vitro, in vivo
studies have not confirmed the existence of long-lived interactions
between these two cell types (Beuneu et al, 2009).
In the present work, we provide evidence that during an LPS-
mediated inflammatory response, only NK cells resident in the
LPS-draining lymph node at the moment of LPS administration are
efficiently and transiently activated. Also, activated NK cells exert
anti-tumor functions by leaving the lymph node and reaching the
tumor. The activation of lymph node-resident NK cells is transient
unless the inflammatory stimulus persists. When repeated injections
of LPS are made to protract inflammation, NK cells functions are
boosted, leading to persistent anti-tumor activity. Finally, we show
that in order to induce NK-cell activation, prolonged interactions are
established between NK cells and DCs at the lymph node draining
the inflammatory stimulus. The prolonged contacts between DCs
and NK cells allow DC-derived IL-18, produced at very low levels, to
efficiently activate DC-interacting NK cells.
Results
DC-mediated activation of anti-tumor NK-cell functions occurs in
the lymph node
The importance of the lymph node as a site of activation of anti-
tumor NK-cell effector functions was evaluated in vivo. Mice were
transplanted in the deep derma with the colon carcinoma CT26 cell
line and 1 day later injected s.c. with LPS in the area draining the
tumor site. Following a single LPS administration, a significant
reduction in tumor growth was observable 5 days after tumor
implant (Fig 1A). The tumor growth reduction was due to the
effector functions of NK cells activated by DCs. Mice that were
depleted of either CD11c+ or NK cells lost the protective effect of
LPS administration (Fig 1B), and the same reduction of tumor
growth was observed in SCID mice lacking T, NKT, and B cells
(Fig 1C). In agreement with a transient capacity of LPS to activate
NK cells, the effect of a single injection of LPS on tumor growth was
short-term and was already lost 8 days after tumor injection
(Fig 1A). Administering LPS every 4 days induced a persistent
decrease in tumor expansion (Fig 1D). Following peripheral LPS
administration, increased numbers of NK cells were observed inside
the tumor. Also in this case, the increase in tumor-associated NK
cell was dependent on DCs (Fig 1E). Since IFN-c has been shown to
interfere with tumor angiogenesis, we measured the level of tumor
vascularization in animals treated or not with LPS. LPS-treated
animals showed not only a reduced tumor volume but also a
decreased perfusion of tumor masses as shown by immunohisto-
chemistry (Fig 2). To investigate whether the NK cells activated in
the draining lymph nodes were, in fact, responsible for the anti-
tumor effect, the egress of cells from lymph nodes was reduced by
treating mice with high doses of FTY720 (Mayer et al, 2004) before
LPS treatment. FTY720 is known to reduce NK cell egress from
secondary lymphoid organs by binding and downregulating the S1P
receptor family, especially S1P1 (Matloubian et al, 2004), without
altering NK cell effector functions, including cytokine production
and cytotoxic activity (Jenne et al, 2009). Consistent with the litera-
ture, we confirmed that FTY720 administration did not interfere
with NK-cell activation, while it reduced activated NK-cell egress
from the draining lymph node (Fig 3A and B). Mice were therefore
treated with FTY720 and/or LPS as depicted in Fig 3C, and tumor
volume evaluated at Day 5. No anti-tumor effect (Fig 3C) and no
increase in IFN-c+ NK cells within the tumor (Fig 3D) were
observed after FTY720 treatment. These data support a model in
which DCs activate NK cells within the lymph node in response to
LPS stimulation leading to subsequent NK-cell egress and manifesta-
tion of anti-tumor function at the tumor site.
LPS does not induce NK-cell recruitment early after
administration and favors activation of NK cells already
resident in the lymph node
We then investigated whether the NK cells activated in the lymph
nodes and responsible for the anti-tumor effect following LPS
administration were already resident in the lymph node or newly
recruited. For this purpose, mice were first transplanted with
tumor cells and then treated with LPS 1 day after tumor cell injec-
tion. The entry of NK cells in the lymph nodes through HEVs was
blocked by systemically treating the mice with the anti-CD62L
antibody 24 h before LPS administration. We observed that total
lymph node cellularity decreased (Appendix Fig S1A) indicative of
the fact that lymphoid cells continuously recirculate. Since abso-
lute NK-cell numbers also strongly diminished (Fig 4A), these data
demonstrate that also NK cells recirculate like other leukocytes.
The percentage of NK-cell numbers in the lymph node, neverthe-
less, increased by 5 times (Appendix Fig S1B), in both draining
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and non-draining lymph nodes. These data suggest that the rate
of recirculation at the steady state of other cell types, such as
T cells, is higher compared to NK cells and potentially exclude a
major role for PSGL-1/P-selectin-mediated LN recruitment of NK
cells in our mouse model. When we analyzed the absolute
numbers of IFN-c+ NK cells in the draining lymph node, we
observed that inhibiting HEV-dependent cell recruitment to lymph
node did not hamper NK-cell activation (Fig 4B). In particular,
although the absolute numbers of IFN-c+ NK cells at the steady
state were changed upon antibody treatment due to the reduced
numbers of NK cells present in the lymph node, the numbers of
newly activated NK cells after LPS administration (IFN-c+ NK-cell
numbers in treated minus the numbers of IFN-c+ NK cells in
untreated animals) were only minimally affected in mice treated
with anti-CD62L. This suggested that blood-borne NK cells
contributed only minimally to the pool of activated NK cells.
The recruitment, over the regular homeostatic turnover, of NK
cells from blood induced by LPS was observable after at least 12
hours (Fig 4A) and occurred after the egress of early-activated
NK cells.
To further demonstrate that lymph node-resident NK cells are the
ones preferentially activated at the time of LPS administration,
CFSE-labeled NK cells were adoptively transferred at the same time
in which the mice received LPS. The presence of labeled NK cells
and their activation were then evaluated 5 hours after LPS adminis-
tration in the draining and the contralateral lymph nodes. The
prediction was that if NK cells were actively recruited by LPS at the
inflamed lymph node for their activation, a larger number of CFSE+
cells should have been found at the draining lymph node compared
to the contralateral one. We observed that labeled NK cells injected
at the time of LPS administration reached the draining and the
contralateral lymph nodes with equal efficiency, suggesting homeo-
static turnover rather than active recruitment (Fig 4C). This
excludes that LPS favors NK-cell recruitment early after administra-
tion and suggests that NK cells do not need to be newly recruited
from the pool of circulating cells to be activated (Fig 4C). Also, frac-
tions of IFN-c+ NK cells observed in the CFSE-positive and CFSE-
negative populations were comparable in the LPS-draining lymph
node (Fig 4D). This again confirmed the prediction that NK cells are
not newly recruited to the inflamed lymph node to be activated.
These experiments support the scenario that NK cells resident in
lymph nodes at the time of stimulus administration are the cells that
preferentially undergo activation.
To investigate whether the activation of lymph node-resident NK
cells was sufficient to reduce tumor growth, we measured the tumor
mass at Day 5 in anti-CD62L-treated animals. Figure 4E shows that
A
D E
B C
Figure 1. Anti-tumor effector functions of NK cells after LPS administration.
A Tumor volume at the indicated time points after CT26 cell transplant in mice treated or not with LPS, n (number of animals per group) = 6.
B Tumor volume in mice depleted of DCs or NK cells before tumor cell transplant and LPS administration, n (number of animals per group) = 5.
C Tumor volume in SCID mice treated or not with LPS, n (number of animals per group) = 5.
D Tumor volume at the indicated time point after repetitive LPS injections as depicted in the bottom scheme, n (number of animals per group) = 6.
E Percent of NK cells within the tumor in mice treated or not with LPS and depleted or not of DCs, n (number of animals per group) ≥ 4.
Data information: NT, control; DT, diphtheria toxin-treated animals to deplete DCs; LPS, mice treated with LPS. Error bars depict SEM. Statistical significance was
determined with a two-tailed t-test. NT, untreated.
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blocking NK-cell recruitment to the lymph node does not hamper
NK cell-dependent control of tumor growth. Accordingly, an
increase in IFN-c+ NK cells could be observed inside the tumor
(Fig 4F). These data suggest that lymph node-resident NK cells that
are activated in response to LPS injection are sufficient to control
peripheral tumor growth.
Taken together, these results indicate that following LPS admin-
istration, lymph node-resident NK cells are unique for their capacity
to become effector cells by interacting with CD11c+ cells. DC-
activated lymph node-resident NK cells egress the lymph node,
reach the tumor, and are preferential effectors in the control of
tumor growth.
During inflammation, DCs make prolonged contacts with NK cells
in lymph nodes
Based on the above results, the lymph node represents the princi-
pal site of NK-cell activation. Lymph nodes are secondary
lymphoid organs where cell–cell contacts are favored due to the
high cell density. It has been repeatedly proposed that analogous
to what happens for T cells, a productive DC–NK-cell cross talk
requires cell–cell interaction and the formation of immune
synapses where NK cell-activating molecules are concentrated and
secreted, likely in a polarized way (Borg et al, 2004; Barreira da
Silva et al, 2011). This requirement has been, then, questioned
since no stable DC–NK-cell contacts have been identified in vivo
when polyI:C or LPS was used to activate DCs (Beuneu et al,
2009). Due to the observation that lymph nodes are preferential
sites for NK-cell activation by accessory cells, we have reconsid-
ered the possibility that long-lasting interactions between DCs and
NK cells could occur in these secondary organs specialized for
lymphocyte activation.
We decided, therefore, to re-analyze the capacity of these two cell
types to interact in lymph nodes ex vivo. We reasoned that potential
long-lived interactions between DCs and NK cells might have been
overlooked simply because of their low frequency, as suggested by the
low percentage, around 10–12%, of NK cells undergoing full activation
in LPS-draining lymph nodes (Figs 3 and 4) (Zanoni et al, 2013).
The distribution and the motility of NK cells were assessed by
means of two-photon microscopy in explanted lymph nodes as
described previously (Caccia et al, 2008). Mice were adoptively
transferred with fluorescently labeled cells, which populated the
popliteal and brachial lymph nodes about 24 h after injection and
persisted for at least 72 h. Imaging was performed in explanted
lymph nodes (Caccia et al, 2008), and cell tracking was performed
by means of the 3D tracking routine the Volocity software (Rush
et al, 2009). Cellular dynamics can be described by several parame-
ters, and for many of them, we noticed high consistency between
our data and published reports, thus validating our approach. For
instance, in agreement with previous studies showing the location
of endogenous NK cells (Beuneu et al, 2009), we found that also
transferred exogenous NK cells distributed mainly at the border of
the T-cell area in Appendix Fig S2. We also confirmed that non-
activated NK cells were highly motile in steady state conditions.
Indeed, mean three-dimensional (3D) velocities of transferred NK
cells, as measured in our experiments (Appendix Fig S3A),
A B
Figure 2. Effect of LPS on tumor vascularization.
A Explanted tumors at Day 12 after repetitive injections of LPS as depicted in the scheme at the bottom of the panel.
B Detection of blood vessels by immunohistochemistry using anti-CD31 antibody (brown staining) in frozen sections of tumors from mice treated or not with LPS as in
the scheme in (A). Nuclei are stained with hematoxylin. Two representative sections are shown, magnification 20×. Left-panel scale bars, 500 lm; right-panel scale
bars, 100 lm. Quantification of vessel mean dimensions and area coverage by vessels is also shown. Three sections from three tumors were analyzed. Error bars
depict SEM. Statistical significance was determined with a two-tailed t-test. NT, untreated.
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overlapped with data available for endogenous NK cells (Beuneu
et al, 2009). Finally, as a further validation of our ex vivo experi-
mental setup on explanted lymph nodes (Villa et al, 2010), we
analyzed the motility of T cells. We found that their average instan-
taneous speed was 10  2 lm/min (Appendix Fig S3B), in agree-
ment with available data (Miller et al, 2002). Given the good
correlation of our results with the literature, we concluded that the
ex vivo setup with adoptively transferred NK cells could be appropri-
ately used to define the behavior of NK cells and DCs in resting and
inflammatory conditions.
Intact brachial lymph nodes explanted from CD11c.GFP mice
(Jung et al, 2002), earlier on adoptively transferred with CMTPX-
labeled NK cells and treated or not with LPS, were imaged. Since
the kinetic of IFN-c production showed a maximal peak of activa-
tion at 5 hours after LPS administration (Zanoni et al, 2013), we
started imaging lymph nodes between 2 and 4 hours after LPS
injection. Three different parameters, namely the confinement ratio
of NK-cell trajectory (defined as the ratio of the distance run by an
NK cell to the trace length), the instant velocity, and the NK-cell–DC
distance, were taken into account to define the dynamics of NK cells
and their possible interactions with DCs. These parameters and the
experimental conditions are extensively explained in the Appendix
(section “Analysis of DC and NK cell interactions”). In our hands,
each parameter, when taken alone, showed poor performance in
defining whether selected DCs and NK cells were interacting.
Conversely, by integrating information coming from each of these
three parameters, we could quantify with a user-independent algo-
rithm whether the selected couple of NK cells and DCs were inter-
acting. In particular, we set upper thresholds on the interacting NK-
cell speed (≤ 60% of the speed averaged over all the tracked cells in
a field of view; Appendix Fig S4) and the DC–NK-cell distance
(d ≤ 25 lm) and required that the confinement ratio was a non-
increasing function of the time (see Appendix for details;
Appendix Fig S5).
We define that a selected NK cell is interacting with a DC in the
ith frame if the conditions on the instantaneous speed (Equation 4
A
C D
B
Figure 3. Anti-tumor effector NK cells are generated in the lymph node.
A, B Absolute numbers of IFN-c+ and total NK cells in draining lymph nodes at the indicated time points before and after LPS administration in mice treated or not
with FTY720 (25 lg/mouse) to reduce the ingress of lymphocytes in the efferent lymphatics.
C Tumor volume in mice treated or not with LPS and/or FTY720 according to the scheme.
D Percent of IFN-c+ NK cells within the tumor in mice treated or not with LPS and with FTY720.
Data information: n (number of animals per group) = 4. Error bars depict SEM. FTY: FTY720. Statistical significance was determined with a two-tailed t-test. NT,
untreated.
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in Appendix), the confinement ratio (Equation 8 in Appendix), and
the NK–DC distance (Equations 1 and 2 in Appendix) are simultane-
ously met. Such frames can be highlighted in the plots of the con-
finement ratio, the normalized NK speed vNorm(ti) (Equation 3 in
Appendix), and the digitized NK–DC distance, DistD(ti) (Equations 1
and 2 in Appendix), by selecting those sets of contiguous frames
for which the three following conditions are simultaneously met:
The confinement ratio is a constant or decreasing function of time,
vNorm(ti) = 0 and DistD(ti) = 0.15. An example is given in Fig 5,
where positively selected frames are marked by red striped boxes.
The plots in Fig 5B and C report the interaction parameters over
time of DCs labeled as DC1, DC2, and DC4 in the image (Fig 5A).
Panel 5B corresponds to the absence of interactions between the
NK cell (the red one in the image in Fig 5A) and the DC1, and panel
5C displays only short interactions, while panel 5D reports a
long-lasting and a short-lived interaction. The duration of the
interactions can then be estimated from these plots and used for
statistical analysis. As discussed below, the definition of interacting
events would be dramatically poorer if only one parameter at a time
was used.
It is likely that this multiple conditioning of the data set slightly
underestimates the number of the interactions but it largely reduces
the number of false NK–DC interactions detected, and it allows us to
measure the interaction times and perform their statistical analysis.
Moreover, the algorithm offers the possibility to single out interac-
tions on a quantitative and reproducible basis.
Using plots like the ones shown in Fig 5, we identified DC-
interacting NK cells (Fig 6A). We found that around 45  4% of the
tracked NK cells interacted with DCs at the steady state. This
percentage increased slightly after LPS administration, reaching
52  6%.
We then focused on cells displaying contacts lasting more than
900 seconds (long interactions). At the steady state, we observed
that most interacting NK cells displayed “touch and go” interactions
(< 5 s) (Movies EV1 and EV2). On average, only 1% underwent
long interactions with DCs. Diversely, in the presence of LPS, a rele-
vant fraction of NK cells (12  2% of interacting cells) experienced
long interactions with DCs. In many cases, these interactions lasted
more than 1/2 h (Fig 6B; see also Movies EV3–EV6). However, the
mean 3D velocities of interacting cells were very similar, regardless
A
D E F
B C
Figure 4. Blocking NK-cell recruitment at the draining lymph node does not interfere with the generation of effector NK cells.
A Absolute numbers of NK cells in one of the four draining lymph nodes in mice treated or not with the anti-CD62L antibody to inhibit NK-cell ingress in the lymph
node from blood. Where indicated, mice were challenged with LPS.
B Absolute numbers of IFN-c+ NK cells in one of the four draining lymph nodes before and after LPS administration in mice in which NK-cell entry in the lymph node
was blocked or not by anti-CD62L treatment.
C (Left panel) Absolute numbers of endogenous and adoptively transferred (CFSE+) NK cells in the draining and contralateral lymph node 5 h after LPS administration;
(right panel) percent of endogenous and adoptively transferred NK cells on total lymphocytes in the draining and contralateral lymph node 5 h after LPS
administration.
D Flow cytometry analysis of LPS-draining and contralateral lymph node from mice that received CFSE-labeled cells at the moment of LPS administration. Lymph node
cells were stained with anti-CD3, anti-DX5, and anti-IFN-c antibodies, and the analysis was performed on gated CD3DX5high cells. One representative of four
independent experiments is shown.
E Tumor volume in mice treated or not with LPS; where indicated, mice received anti-CD62L antibody 12 h before LPS treatment.
F Percent of IFN-c+ NK cells within the tumor in mice treated or not with LPS and with the anti-CD62L antibody.
Data information: (A, B, C, E, F) n (number of animals per group) = 4. Error bars depict SEM. Statistical significance was determined with a two-tailed t-test. NT,
untreated.
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of the presence or absence of LPS (Fig 6C). This is presumably
because cells showing long interacting time are too few to impact
on the general mean velocity.
In summary, prolonged interactions between DCs and NK cells
occur in the peripheral T-cell area of the lymph nodes in LPS-
induced inflammatory conditions.
IL-18 is the proximity-dependent signal required in
DC–NK-cell interactions
The two-photon microscopy studies described above indicated that
a productive DC–NK-cell interaction demands the formation of
stable contacts. That requirement might be interpreted as depen-
dence on a plasma membrane protein on DCs that must interact
with an NK-cell receptor. Nevertheless, others and we observed
that in the presence of LPS, only soluble—and not membrane-
associated—DC-derived molecules are required for NK-cell
activation. In particular, IL-12, IL-18, and type I IFNs in humans
(Ferlazzo et al, 2004; Chijioke & Munz, 2013) and IL-2, IL-18, and
type I IFNs in the mouse (Zanoni et al, 2013) are necessary and suf-
ficient to drive DC-mediated NK-cell activation. Type I IFNs are in
turn necessary to induce IL-15 production (Lucas et al, 2007).
The alternative explanation for the prolonged interaction
observed between DCs and NK cells in inflammatory conditions in
the lymph node may be that certain soluble factors are released in
such low amounts to be effective only in the limited space surround-
ing the secretion source, where the local concentration is high
enough. In this way, they would behave as proximity-dependent
signals, despite their soluble nature.
We previously demonstrated that among the factors required for
NK-cell activation, IL-12, IL-2, and type I IFNs are produced by DCs
in sufficient amount to work on bystander cells (Zanoni et al,
2013).
A candidate cytokine possibly requiring synapse formation to be
effective is IL-15. IL-15 is described to be required for NK-cell activa-
tion in the presence of LPS and transpresented in association with
IL-15Ra. Nevertheless, others and we have shown that both in
humans and in mice, IL-15 can act in an autocrine way on NK cells
expressing the IL-15Ra via cis-presentation (Zanoni et al, 2013;
Mattiola et al, 2015), therefore excluding the necessity of DC–NK-
cell contact.
Interestingly, it has been shown that IL-18 is secreted at the
immune synapse between human DCs and NK cells (Gardella et al,
1999; Semino et al, 2005). Thus, it could well exhibit the properties
of a contact-dependent, although soluble, factor. The precursor of
IL-18 is almost ubiquitously expressed, while active IL-18 is gener-
ated in very limited amount only in specific cells, including DCs and
macrophages (Dinarello et al, 2013).
In vivo and in vitro, IL-18 produced by DC is required for NK-cell
activation. In our previous work (Zanoni et al, 2013), we observed
that the activation of NK cells following LPS administration was
severely compromised in chimeric mice in which only DCs were
deprived of the ability to produce IL-18. Accordingly, no NK-cell
activation could be observed in vitro in the presence of LPS when
IL-18R-deficient NK cells or IL-18-deficient DCs were cocultured
with WT DCs or WT NK cells, respectively.
We first investigated whether IL-18 is secreted at the contact
site between DCs and NK cells also in the mouse system. These
two cell types were cocultured in the presence of LPS, and the
localization of IL-18 was analyzed by immunofluorescence after
2 h of incubation. As shown in Fig 7A, IL-18 redistributed at
the contact sites between the two cell types in LPS-treated
cocultures.
To test whether IL-18 was the contact-dependent signal required
in DC-mediated NK-cell activation, we reasoned that naturally
secreted IL-18, once dispersed in the culture medium, should be
ineffective due to dilution. Therefore, we expected supernatants
collected from LPS-stimulated DCs to be unable to elicit IFN-c
release by NK cells, unless rIL-18 was added. Indeed, that was
proven to be the case (Fig 7B). Similarly, in a transwell culture
system used to separate DCs and NK cells, IL-18 had to be added to
the compartment containing NK cells in order to see their activation
(Fig 7C).
These data establish that IL-18 is a proximity-dependent signal
that requires a prolonged contact between DCs and NK cells to fully
exert its activity.
A B C D
Figure 5. DC–NK-cell interactions in lymph nodes.
A Representative image of an NK cell (red) interacting with four DCs (green).
B–D Plot of the confinement ratio (CR, black squares), the normalized NK speed (red circles), and the digitalized NK–DC distance, DistD(ti) (green triangles), as a function
of time for the NK cell reported in the image. Panels (B–D) correspond respectively to the interaction with the DC1, DC2, and DC4 displayed in (A). For reference,
also the normalized distance Dist(ti) is reported in the plots (blue down-triangles). The time periods in which all the three conditions discussed in the text are
fulfilled are marked with red striped rectangles in the plots. The green up-triangles indicate the parameter TonToff defined as TonToff = 1 if Dist(ti) < d = 25 lm
and TonToff = 1 if Dist(ti) ≥ d and indicate the putative interactions according to a more simplified algorithm based on the DC–NK-cell distance alone.
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Discussion
Understanding NK-cell distribution, site of activation, and trafficking
is necessary to define immunization protocols aimed at reactivating
protecting and persisting host anti-tumor functions. In the present
work, we show that after the s.c. administration of LPS in the area
draining a tumor site, NK cells activate their anti-tumor functions.
Draining lymph node-resident NK cells, and not cells newly
recruited from blood or non-lymphoid tissue, are activated by DCs,
leave the lymph node, reach the tumor, and decrease tumor growth.
The effect is only temporary, and continuous LPS administrations
are necessary to maintain NK-cell anti-tumor effector functions. The
DC-mediated activation of lymph node-resident NK cells correlated
with the formation of relatively long-lasting interactions between
the two cell types. This allows IL-18, a DC-derived cytokine required
for NK-cell activation and produced in extremely low amount, to
efficiently act in a paracrine way at the interface between the two
interacting cells.
NK cells mediate tumor suppression exploiting different mecha-
nisms, including direct killing of tumor cells and IFN-c production.
IFN-c is, in turn, required to activate type I immunity (Lee et al,
2015) and to interfere with tumor neovascularization (Curnis et al,
2005; Deng et al, 2014). CT26 cells are relatively insensitive to IFN-
c-induced type I immunity and cytotoxicity since IFN-c downregu-
lates a CD8+ cell epitope favoring tumor escape (Beatty & Paterson,
2000); therefore, the anti-tumor effect mediated by NK cells is
presumably not due to the activation of adaptive immunity. Accord-
ingly, we observed that the LPS-mediated anti-tumor effect was
present also in SCID mice lacking T and B cells. The primary IFN-c-
dependent anti-tumor effect exerted by NK cells in this model is
presumably the anti-angiogenic function. We observed that the acti-
vation of NK cells significantly affected tumor vascularization with
LPS-treated animals showing a reduced amount of vessels perfusing
the tumor with a more regular distribution. The effect on tumor
vascularization could be directly due to an anti-angiogenic effect of
IFN-c. An intriguing alternative is that IFN-c release at the tumor
site by activated NK cells could exert an inhibitory effect on tumor--
associated neutrophil (TAN) recruitment. Evidence in the literature
is present showing an inhibitory effect of NK cell-derived IFN-c on
neutrophil recruitment at the inflammation site in autoimmune and
infection-mediated inflammatory conditions (Feng et al, 2006;
Figueiredo et al, 2007; Wu et al, 2007). Further experiments will be
performed in the future to confirm the existence of one or both
scenarios.
In our study, the lymph node draining the inflammatory stimulus
is the site of activation of NK cells. Blocking blood-borne NK-cell entry
in the lymph node does not affect NK-cell activation and anti-tumor
NK-cell functions, indicating that lymph node-resident NK cells at the
moment of LPS activation are the first cells to be activated. After
activation, NK cells leave the lymph node to reach the tumor site.
Reduction of activated NK-cell exit from the inflamed lymph node
completely eliminates the NK-cell anti-tumor functions observed after
LPS treatment, indicating that the lymph node is the exclusive site of
NK-cell activation in these conditions. Based on studies describing the
presence of CD56bright perforinlow in human seroma, it has been
hypothesized that NK cells can leave the tissues and reach secondary
lymphoid organs via the lymph (Carrega et al, 2014). Although we
cannot formally rule out that some NK cells can be recruited from skin
and arrive to the draining lymph node via the afferent lymphatics, we
tend to exclude that those cells are the ones predominantly contribut-
ing to the observed anti-tumor NK-cell functions. LPS is quickly
cleared from the skin by immediate drainage to lymph nodes as well
as local inactivation by de-acylation (Lu & Munford, 2011).
In the lymph node, NK cells distribute in the T-cell area where
DCs are present in high concentration forming an intricate net of
cells (Beuneu et al, 2009). The high cell density is a strategic organi-
zation to favor cell–cell interactions. In this context, T cells, probing
one DC after another, increase the probability to find the DCs
equipped for their activation and establish long-lasting interaction
with these cells. Since the lymph node represents the principal site
of NK-cell activation, we predicted that analogous to what happens
for T cells, also NK cells needed to find the DCs correctly prepared
for their activation and to establish long-lasting interactions with
them.
A
B
C
Figure 6. DCs and NK cells establish prolonged interactions in lymph
nodes upon LPS injection.
A NK and DC trajectories as they are tracked by Volocity software on the 4D
volumes collected in lymph nodes on the TPE microscope. The sequence of
images shows the interaction between an NK cell (red) and a DC (green).
In the top panels, the NK cell moves according to a directional random
motion, while in the lower left and middle panels, the NK cell seems to
recognize the DC and to go back. In the right lower panel, the stable
contact DC–NK cell is clearly visible.
B Time duration of the DC–NK contacts in steady state (LPS) and
inflammatory (+LPS) conditions. Bars indicate the mean of the distribution.
The percent of cells showing long interaction times (≥ 15 min) is shown.
C NK-cell 3D velocities. 3D velocities of NK cells taking contacts with DCs
before (black) and 5 h (green) after LPS treatment.
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Different from a previous work (Beuneu et al, 2009), we found
that following LPS administration, NK cells stabilize their contacts
with DCs, most likely to allow enough time to receive the activating
stimuli. Indeed, the analysis of trajectories revealed that NK cells
show a decrease in their motility in inflammatory conditions when
compared to the steady state condition. Moreover, NK cells interact-
ing with DCs transition from a “touch and go” regime at the steady
state, in which short and numerous contacts with DCs are formed,
to longer, long-lived contacts (Fig 5). We were able to reveal DC–
NK-cell long interactions, overlooked in previous reports (Beuneu
et al, 2009), thanks to the definition of a new method of measuring
the NK–DC interaction times, possibly independent of the user direct
inspection of the microscope movies and based on the computing
and combination of a number of dynamic parameters. This choice
was required for the highly dynamic behavior of NK cells displaying
widely varying interaction times. We focused here on three parame-
ters, namely the NK–DC distance, the instantaneous NK-cell veloc-
ity, and the confinement ratio. The rationale in the choice of the
indicated parameters was that cell–cell interaction is mediated by
the emission of chemical signals that imply NK cells lie in close
proximity to a DC for a finite time stretch and display velocity
slightly lower than the average. The requirement on the reduction
of the confinement ratio further ensures that the interaction, though
highly dynamic in character, lasts for a finite stretch of time.
The algorithm devised here enforces a strict series of constraints
on the trajectory that avoid us to take as a real interaction a situa-
tion in which the NK–DC distance alone is low but the speed and
the confinement ratio constrains are not satisfied. In our opinion,
these situations correspond to instances in which the cells are not
interacting but probably only passing by, as shown in the examples
reported in the Appendix (Appendix Figs S6–S11). On the other
hand, we have refined the computation of the interaction duration
by specifically allowing that the fulfillment of the three criteria can
fail for a single image and for a single parameter.
At first look, our data may seem to conflict with previous results
by Beuneu et al (2009), who reported no or very few interactions
lasting more than 5 min (300 s). However, careful inspection of
their work indicates that the percentage of NK–DC interactions last-
ing more than 300 s (the maximum duration reported) at 2–4 h was
about 12%. Although with some uncertainty, this estimate agrees
with our results. Our analysis extends and refines previous analyti-
cal strategies, highlighting a small but finite fraction of long-lasting
interactions positively correlating with cell biology data.
These data are in agreement with previous in vitro studies show-
ing that NK cells and DCs form stable conjugates necessary for NK-
cell activation, with the corresponding immunologic synapse
enriched in adhesion molecules and inflammatory cytokines
(Barreira da Silva & Munz, 2011).
Interestingly, it has been repeatedly shown that productive DC–
NK-cell interactions require both soluble and contact-dependent
signals (Fernandez et al, 1999; Newman & Riley, 2007). However,
others and we demonstrated that soluble cytokines at physiological
concentrations are able to fully activate NK cells in terms of IFN-c
production. This seeming discrepancy might be explained by the
peculiar biology of IL-18. When the amount of released cytokine is
low, a biologically active concentration might be achieved only in
close proximity to the secretion source. However, upon dispersion,
the concentration would drop to levels yielding a negligible activity.
In this way, even soluble signals would behave like contact-
dependent signals.
In agreement with the observed concentration of IL-18 at the cell
contact sites, supernatants from LPS-stimulated DCs are not able to
activate NK cells, unless supplemented with an excess of rIL-18,
confirming that the confined secretion of IL-18 at physiological
doses imposes a requirement of cell–cell contact in DC-mediated
NK-cell activation (Fig 7).
Obviously, the IL-18-driven requirement for cell contact is in
addition to adhesion molecules, such as integrins, building the
architecture of the immune synapse (Sims & Dustin, 2002; Brilot
A
B C
Figure 7. IL-18 is the contact-dependent signal required in DC–NK-cell
interactions.
A Differential interference contrast images (left panels) and confocal
microscopy analysis of IL-18 (right panels) in a DC/NK conjugate after 2 h
of coculture in the presence of LPS and in unstimulated cells (NT).
Representative images from 3 experiments are shown, magnification 63×.
Scale bars, 4.36 lm.
B IFN-c release by NK cells cultured in the presence of supernatants
recovered from untreated DCs (untreated) or DCs treated O/N with LPS
(LPS). Where indicated, IL-18 was added to the cultures.
C Cell contact-dependent activation of NK cells by DCs depends on IL-18.
Unstimulated or LPS-activated DCs and NK cells were cocultured in the
same wells (DC + NK + LPS) or separated by a porous membrane
[(DC + LPS)/NK]. Where indicated, IL-18 was added to the transwells
[(DCs + LPS)/(NK + IL-18)]. NK cells alone were also cultured in the
presence of the three selected cytokines: IL-2 and IFN-b in the upper
chamber and IL-18 in the lower chamber. IFN-c in the supernatant was
then measured by ELISA after 8 h of coculture.
Data information: (B, C) n (number of independent experiments) = 3. Error
bars depict SEM.
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et al, 2007). Indeed, the formation of a stable physical interaction
between accessory cells and lymphocytes is a precondition of activa-
tion, and DC–NK-cell interactions make no exception. Only when
the structure of the immune synapse is in place, are cytokines polar-
ized and released (Borg et al, 2004; Brilot et al, 2007). Therefore,
disruptions of key adhesion molecules would likely result in loss of
activation as well. However, this would merely be a consequence of
the lack of structural (rather than functional) requirements. We did
not investigate the molecular requirements at a structural level here;
rather, our claim is that IL-18 needs cell contact at a functional level
(Fig 7).
Overall, our findings shed new light on the complex events that
lead to the development of effective NK cell-mediated responses.
We found that DC–NK-cell interactions at the draining lymph node
are essential to activate NK cells and that lymph node activated NK
cells retain a unique capacity to mount effective anti-tumor
responses. Blocking activated NK-cell egress from the lymph node
completely abrogated the NK cell-protective effect against tumor
growth. The development of anti-tumor therapies aimed at boosting
innate immune lymphocyte functions should take into account these
requirements in order to potentiate our capacity to fight tumor
growth and spread.
Materials and Methods
Mice
All mice, housed under specific pathogen-free conditions, were
female on a BALB/c background for at least 12 generations and
were used at 7–12 weeks of age. WT and SCID animals were
supplied by ENVIGO, Italy, and used at 7–12 weeks of age. DTR
mice, expressing the diphtheria toxin receptor under the CD11c
promoter, have been already described (Jung et al, 2002). Experi-
ments were performed using protocols approved by the Institutional
Animal Care and Use Committee of the University of Milano-Bicocca
and by the Italian Ministry of Health. Mice were kept in a pathogen-
free conventional animal house facility. The animal house is run by
professional employees fully equipped with state-of-the-art instru-
mentation in order to maintain the standard of animal welfare at the
maximum levels. All mice were housed in individual, ventilated
cages (IVCs) with 12-h light/dark cycles with food and water
ad libitum.
To prevent pain or distress, we avoided restraining animals for
longer than 5 min at a time, for most of the procedures performed.
For tumor cell injections, mice were anesthetized by i.p. injection
with ketamine (80–100 mg/kg) and xylazine (10 mg/kg), premixed
before application. Mice subjected to tumor injection were moni-
tored on a daily basis for signs of discomfort, including hunched
posture, ruffled fur, and lack of movement within the cage. The
body condition score index (a qualitative assessment of an animal’s
overall appearance based on its weight, muscle mass, and bone
prominence) was used to evaluate the welfare of the mice. Gener-
ally, mice did not present signs of distress given the short period of
time between tumor injection and killing.
Each experiment depicted in the figures was repeated at least
twice with at least four mice per group. Globally, around 600
BALB/c animals (WT or genetically modified) were used.
Reagents
Hybridoma producing anti-L-selectin monoclonal antibody Mel-14
was grown and the antibody purified according to standard proce-
dures. FTY720 was purchased from Sigma-Aldrich. TLR-grade Re-
form LPS from E. coli serotype R515 was purchased from Enzo Life
Sciences. The antibodies used were as follows: anti-asialo GM1
(Functional Grade Purified, cat. no. 16-6507; eBioscience); PE anti--
mouse CD49b (clone DX5, cat. no. 108908; Biolegend); APC
anti-mouse IFN-c (clone XMG1.2, cat. no. 505810; Biolegend); FITC
anti-mouse CD3 (clone 17A2, cat. no. 100204; Biolegend); APC anti-
mouse CD11c (clone N418, cat. no. 117310; Biolegend); APC/Cy7
anti-mouse CD3 (clone 17A2, cat. no. 100222; Biolegend); purified
anti-mouse CD31 (clone MEC 13.3, cat. no. 102502; Biolegend); PE/
Cy7 anti-mouse CD45.2 (clone 104, cat. no. 109830; Biolegend); and
anti-IL-18 polyclonal antibody (cat. no. sc-7954-Y; Santa Cruz
Biotechnology).
Cells
All cells were cultured in IMDM-10 complete medium: IMDM, 10%
heat-inactivated FBS (EuroClone), 2 mM L-glutamine, 100 U/ml
penicillin, 100 lg/ml streptomycin, and 50 lM 2-mercaptoethanol
(Sigma-Aldrich).
CT26 cell line (ATCC, CRL2638), a BALB/c mouse colon carci-
noma, was obtained from Mario Colombo (Istituto Nazionale del
Tumori, Milan, Italy).
BM-derived DCs (BM-DCs) were generated by culturing BM
precursors, flushed from femurs, in GM-CSF-supplemented medium
for 8–10 days, as described (Inaba et al, 1992; Granucci et al,
2001).
NK cells and T cells were purified from RBC-lysed splenocytes by
MACS-positive selection using CD49b (DX5), or CD4 and CD8
microbeads (Miltenyi Biotec), respectively. Purity was assessed by
FACS and was routinely between 93 and 96% for NK cells, and at least
98.5% for T cells. Alternatively, NK cells were first enriched by
MACS-negative selection for Ly-6G (1A8), CD19 (6D5), and CD3e
(145-2C11), using biotinylated Abs and streptavidin microbeads, then
stained with anti-CD49b, and sorted with a FACSAria II (BD Bios-
ciences). Purity was consistently greater than 99.5%. MACS-selected
and FACS-sorted NK cells produced similar results in our experiments.
In vivo experimental settings
For the analysis of anti-tumor effect of NK cells in vivo, mice were
inoculated in the deep derma in the left flank with the minimal
tumorigenic dose of CT26 tumor cells (5 × 104) at Day 0 and with
LPS (10 lg/mouse) at the tumor draining area at Day +1.
To deplete DCs, CD11c.DOG mice received only 1 injection of DT
(300 ng/mouse) at Day 1. To deplete NK cells, mice received anti-
asialo GM1 polyclonal antibodies (eBioscience, 30 lg/mouse i.v.) at
Days 3, 1, and +1.
To measure IFN-c+ NK cells within the tumor, LPS has been
re-injected at Day 5 and IFN-c+ NK cells enumerated 5–6 h after
LPS injection.
In some experiments, mice were also treated with FTY720
(25 lg/mouse) or anti-CD62L (100 lg/mouse) antibody according
to the scheme indicated in the figures.
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Tumor volume (mm3) was calculated according to the following
formula: (diameter1 × diameter2)2/2.
ELISA
Cell-free supernatants were collected from DC–NK-cell cocultures
after 18 h, and they were analyzed using an IFN-c DuoSet ELISA Kit
(R&D Systems). We have previously demonstrated that IFN-c is
exclusively produced by NK cells in DC–NK-cell cocultures (Granucci
et al, 2004).
Immunohistochemistry
Explanted tumors were embedded in OCT freezing media (Bio-
optica). Sections (5 lm) were cut on a Cryostat, adhered to Super-
frost Plus slide (Thermo Scientific), fixed with acetone, and blocked
with PBS containing 0.3% Triton X-100 (Sigma-Aldrich) and 10%
FBS. Sections were then stained with purified anti-mouse CD31 anti-
body (1:200) in blocking buffer, 1 h at room temperature. Sections
were washed with TBS buffer and incubated with Rat-on-Mouse
HRP-Polymer kit (Biocare Medical). Dako EnVision System-HRP
was used as chromogen and counterstain with Mayer’s Hematoxylin
(Bio-optica). After dehydration, stained slides were mounted with
Eukitt and images acquired with a Vs120 dotSlide (Olympus). Image
analysis was performed using FIJI-ImageJ (Schindelin et al, 2012,
2015). ROI color deconvolution was used to separate the DAB
signal, and particle analysis was used to automatically recognize,
count, and measure all the CD31-positive spots within the total
tumor area.
IL-18 detection in DC–NK-cell cocultures
Cells were mixed at an NK cell/DC ratio of 2:1 in 100 ll of
RPMI1640 without serum and pelleted quickly at 228 rcf. The pellets
were then allowed to conjugate for 2 h at 37°C in the presence or
absence of LPS. After conjugation, cells were gently resuspended in
RPMI1640 and centrifugated on coverslips for immunofluorescence
analyses.
Cells were thus fixed in 4% paraformaldehyde for 10 min at
4°C and permeabilized with 0.1% Triton X-100 and 1% BSA for
10 min at room temperature. Cells were finally stained with the
anti-IL-18 antibody in the presence of 5% serum, followed by
the appropriate secondary reagent. All washes were performed in
PBS supplemented with 1% BSA. After staining, slides were
mounted with FluorSaveTM (Calbiochem). Slides were visualized
through a ×63 oil immersion lens with an inverted TCS SP5
(Leica). Serial optical sections (0.3 lm; 15–20 sections) were
acquired.
In vivo NK-cell activation and IFN-c production
To activate NK cells, age-matched mice were injected s.c. with
0.5 lg LPS/gbw. Where indicated, mice received previously CT26
tumor cells or were treated with FTY (25 lg/mouse) or with anti-
CD62L neutralizing antibody (100 lg/mouse).
Mice were euthanized at different time points, and single-cell
suspension of lymph node, skin, or tumors was kept for 3 h, in the
presence of brefeldin A (BFA, 10 lg/ml; Sigma-Aldrich).
Intracellular staining was performed using Cytofix/Cytoperm
reagents (BD Biosciences) according to the manufacturer’s instruc-
tions, with the following Abs: anti-CD49b (DX5 or HMa2), anti-
CD3e (145-2C11), anti-CD11c (HL3), and anti-IFN-c (XMG1.2) (or
its isotype control). Samples were acquired with a Gallios flow
cytometer (Beckman Coulter).
Single-cell suspensions from tumors were obtained using the
mouse Tumor Dissociation Kit from Miltenyi.
Absolute cell numbers were calculated using Flow Count
Fluorospheres (Beckman Coulter) according to the manufacturer’s
recommendations.
Two-photon microscopy
A direct optical microscope (BX51; Olympus) was used for intravital
imaging of DC–NK-cell interactions.
The infrared laser source (Mai Tai HP+DeepSee, Spectra
Physics, USA; with pulses of 120 fs full width at half maximum
and 80 MHz repetition frequency) is coupled through the FV300
(Olympus, Japan) scanning head. All the measurements were
acquired through a 20×, 0.95-NA, 2-mm-WD objective (XLUMPlan
FI; Olympus, Japan). TPE allows limited photodamage of the
samples, simultaneous excitation of multiple fluorescent probes,
and deep penetration in thick tissues such as DLNs. The fluores-
cence signal is steered to a non-descanned unit and split into
three channels (blue, green, and red channel) by two dichroic
beam splitters (Caccia et al, 2008). Additional details on the setup
and its optical characterization can be found in Caccia et al
(2008).
For ex vivo experiments, the entire microscope is surrounded by
a custom-made thermostatic cabinet in which the temperature is
kept at 37°C (air thermostating by “The Cube”; Life Imaging
Services, Basel, CH) and physiological conditions are guaranteed
during the experiments by flowing 37°C buffer solutions saturated
with a mixture of 95% O2–5% CO2.
Volocity (Perkin-Elmer Inc.) was used to analyze recorded
movies. The extracted traces were then analyzed for the measure of
the interaction time by means of a specifically designed MatLab
(MathWorks Inc.) code.
Statistical analysis
Means were compared by paired or unpaired t-tests. Data are
expressed and plotted as means  SEM values. Sample sizes for
each experimental condition are provided in the figure legends.
P-values are provided in the figures. All of the statistical analyses
were performed in blind by a third person.
Expanded View for this article is available online.
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Problem
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cells (DCs) are required for NK-cell activation, and the mechanisms
underlining this process have been well characterized. Yet there is
little information concerning NK-cell trafficking between secondary
lymphoid organ and inflamed or tumoral tissues and the site and
dynamic of NK-cell interaction with accessory cells.
Results
In this study, we provide evidence that following s.c. lipopolysaccha-
ride administration, NK cells are not actively recruited at the draining
lymph node at early time points, but continue their regular homeo-
static turnover. Only NK cells resident in the draining lymph node at
the time of stimulus administration, therefore, become activated and
exert anti-tumor functions by leaving the lymph node and reaching
the tumor. The activation of lymph node-resident NK cells is short-
term unless the inflammatory stimulus persists. The activation of NK
cells at draining lymph nodes correlates with the formation of stable
and prolonged interactions with dendritic cells to allow IL-18, a cyto-
kine produced at very low level by LPS-stimulated DCs, to efficiently
stimulate DC-contacting NK cells.
Impact
These findings provide important advances on the mechanisms of NK-
cell activation in vivo in response to a major inflammatory stimulus.
The understanding of the dynamics governing NK-cell responses will
provide a framework for the generation of immunotherapeutic strate-
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tumor growth and spread.
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